Clinical Trial Update: Nanocort in Acute Exacerbation of Relapsing-Remitting Multiple Sclerosis (MS) [Phase 2]

View source ↗

Summary

A Phase 2 trial of Nanocort for acute exacerbations of relapsing-remitting multiple sclerosis and clinically isolated syndrome has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clinically Isolated Syndrome
• Multiple Sclerosis

Drugs mentioned

• Nanocort

Snippet

Sponsor: Galapagos NV | Conditions: Acute Exacerbation of Remitting Relapsing Multiple Sclerosis, Clinically Isolated Syndrome | Phase 2 | Status: TERMINATED